NCI Division of Cancer Treatment and Diagnosis

Welcome to the NCI Division of Cancer Treatment and Diagnosis (DCTD) LinkedIn page! Led by DCTD Director James H. Doroshow, M.D., our mission is to support the development of novel diagnostic and therapeutic approaches for cancer by expediting the initial and subsequent large-scale testing of new agents, biomarkers, imaging tests, and other diagnostic and therapeutic interven­tions (radiation, surgery, immunotherapy) in patients with cancer. https://dctd.cancer.gov

A SWOG and National Cancer Institute (NCI) NCTN collaborative, randomized phase 3 trial (S1826) assessed patients with stage III or IV newly diagnosed Hodgkin’s lymphoma. Adult and adolescent and young adult patients 12 years and older that received the immunotherapy nivolumab (N) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) had longer progression-free survival compared to patients who received brentuximab vedotin (BV)+AVD. Fewer patients on the N+AVD regimen stopped treatment early and showed a lower incidence of immune-related toxic effects and fewer deaths compared to those on the BV+AVD regimen. Note that radiotherapy was not necessary for the adolescent and young adult patients. Read the publication entitled “Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma”: https://lnkd.in/e3scuYdA and learn more about the impact of the trial: https://lnkd.in/enVCS6XV

The National Cancer Institute (NCI) NCTN/NCORP Data Archive is a centralized, controlled-access database used for storing and sharing of individual-level data generated from clinical trials conducted by the National Clinical Trials Network (NCTN) and the NCI Community Oncology Research Program (NCORP). With some exceptions, the NCTN/NCORP Data Archive includes patient-level clinical data from: - Primary publications of phase 3 trials published as of January 1, 2015 - Selected non-primary publications of phase 3 trials published as of April 1, 2018 - Selected publications of phase 3 trials published prior to January 1, 2015 - Selected publications of phase 2 trials Learn more about the Archive: https://lnkd.in/gKGd3Krg

National Cancer Institute (NCI) is convening a workshop virtually on November 19, 2024 from 1:00 to 3:30 PM ET on “Pharmacological Ascorbate and Cancer Treatment Outcome” to spur discussion, foster collaboration, and identify ways to advance pharmacological ascorbate cancer therapeutics including high dose intravenous application in cancer. Registration is required to attend: https://lnkd.in/eqcDbr-h

DCTD’s Developmental Therapeutics Program is seeking a PHARMACOLOGIST to coordinate and evaluate safety testing of investigational cancer therapies, and to evaluate/develop research protocols and pharmacokinetic study design initiatives. This vacancy is open on USAJOBS on November 18, 2024 and closes on November 22, 2024. Apply below on USAJOBS: https://lnkd.in/e6PbPwNc https://lnkd.in/ePwg4jYT Candidates must be U.S. citizens and able to work in in Rockville, Maryland (some telework allowed). For more information contact Dr. Rose Aurigemma at aurigemr@mail.nih.gov.

Uterine serous cancer (USC) accounts for about 10% of all endometrial cancer (EC) cases but causes 40% of EC deaths. National Cancer Institute (NCI) staff convened a workshop on USC in June 2023 to spur interest in research, identify knowledge gaps, and discuss the marked health disparities seen in this disease. Some opportunities for action identified in the paper are highlighted as follows: - Focusing scientific directions - Expanding, enhancing, and optimizing the use of models, biospecimens, and data resources - Fostering development of the scientific community Communication across stakeholders (scientists, clinicians, consumers, advocates, and industry) in the workshop report, recently published in the Journal of the National Cancer Institute: https://lnkd.in/eSfFbSsH

DCTD’s Developmental Therapeutic Clinic (DTC) is seeking a Clinical Fellow/Senior Clinical Fellow via the Advanced Developmental Therapeutics Training Program (ADTTP) pipeline. The candidate(s) will be primarily responsible for participating in clinical research and refining investigative skillsets e.g., trial design and methodology, protocol development, execution, monitoring, and conformity with ethical standards skills. Applicants must be board certified in medical oncology with an active medical license and completed subspeciality training in adult medical oncology at a U.S. accredited institution. For more information on how to apply or questions regarding this fellowship position, contact Monika Sarna at msarna@mail.nih.gov and visit our Careers page under “Physicians”: https://lnkd.in/ddaqMeG6

MEETING CANCELLED!!! On November 4th at 1:00 pm ET, Dr. Vladimir Ponomarev will discuss advances in imaging in cancer cell therapies at the National Cancer Institute (NCI) Imaging Community Webinar organized by DCTD’s Cancer Imaging Program. Join here: https://lnkd.in/dJtu_5K5

DCTD invites comparative oncology investigators and veterinary oncologists working with pet dogs that develop spontaneous cancers to contribute annotated data to the National Cancer Institute (NCI) Integrated Canine Data Commons (ICDC): https://lnkd.in/eGyFqM_f More information on how to submit data here: https://lnkd.in/eaqgZCMQ. The ICDC is a cloud-based data repository node within the Cancer Research Data Commons (https://lnkd.in/g6weC9br) that permits scientists to explore, analyze, and understand the biological relationships between human and canine cancers. The scientific community can use the ICDC free of charge. The ICDC seeks these types of annotated data: - Genomic, transcriptomic, epigenetic, and proteomic data on canine tumors - Longitudinal data on dogs followed pre-diagnosis, at diagnosis, on therapy, and at recurrence - Information about canine clinical specimens that could be shared with other researchers in the field, as we will be expanding the ICDC to include a repository of specimen data

DCTD’s Cancer Imaging Program is seeking a SUPERVISORY PHYSICIAN (ASSOCIATE DIRECTOR) to plan, conduct, coordinate and evaluate a broad array of national and international laboratory and clinical research programs designed to identify and develop new imaging approaches to the diagnosis and treatment of cancer. This is an exploratory ad to gauge interest. For more information, email your resume to NCIDCTDvacancyinquiry@mail.nih.gov and visit our careers page under “Physicians”: https://lnkd.in/ddaqMeG6